

Edgar Filing: ICU MEDICAL INC/DE - Form 8-K

ICU MEDICAL INC/DE
Form 8-K
January 16, 2004

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) January 15, 2004

ICU MEDICAL, INC.

(Exact name of registrant as specified in its charter)

| | | |
|---|--|--|
| DELAWARE ----- (State or other jurisdiction of incorporation) | 0-19974 ----- (Commission File Number) | 33-0022692 ----- (I.R.S. Employer Identification No.) |
| 951 Calle Amanecer, San Clemente, California ----- (Address of principal executive offices) | | 92673 ----- (Zip Code) |

(949) 366-2183

Registrant's telephone number, including area code

N/A

(Former name or former address, if changed since last report)

INFORMATION TO BE INCLUDED IN THE REPORT

Item 5. Other Events

On January 14, 2004, ICU Medical, Inc. and Abbott Laboratories signed the following agreements, effective as of January 14, 2004, as further described in the press release filed as Exhibit 99.1 hereto: "ICU Medical, Inc. Announces Amendments to Marketing and Distribution Agreements with Abbott Laboratories."

Item 7. Financial Statements and Exhibits

(c) Exhibits

Edgar Filing: ICU MEDICAL INC/DE - Form 8-K

- 10.1 AMENDMENT 11 TO THE SUPPLY AND DISTRIBUTION AGREEMENT BETWEEN ICU MEDICAL SALES, INC. AND ABBOTT LABORATORIES, dated as of January 14, 2004.
- 10.2 AMENDMENT 1 TO THE CO-PROMOTION AND DISTRIBUTION AGREEMENT BETWEEN ICU MEDICAL SALES, INC. AND ABBOTT LABORATORIES, dated as of January 14, 2004.
- 99.1 Press release, dated January 15, 2004 announcing amendments to marketing and distribution agreements with Abbott Laboratories.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 15, 2004

ICU MEDICAL, INC.

/s/ Francis J. O'Brien

Francis J. O'Brien
Secretary, Treasurer and
Chief Financial Officer